2017-05-15T13:18:03-07:00 2016-12-31 204723636 ISLER CPA LLC 1976 GARDEN AVE EUGENE OR 97403 990 2016-01-01 930995453 FANCONI ANEMIA RESEARCH FUND INC FANC 5416874658 1801 WILLAMETTE STREET NO 200 EUGENE OR 97401 KEVIN MCQUEEN PRESIDENT 5416874658 2017-04-21 true GARY ISKRA P00051776 5413425161 2017-05-02 2ECD3D735D034F8F3F680A15750D768D539C5C88 CAC9550E4E212F354AA67904D0E3111C3651A823 2016 2021-01-29 14:40:06Z KEVIN MCQUEEN 1801 WILLAMETTE STREET NO 200 EUGENE OR 97401 3202614 false X WWW.FANCONI.ORG X TO FIND EFFECTIVE TREATMENTS AND A CURE FOR FANCONI ANEMIA AND TO PROVIDE EDUCATION AND SUPPORT SERVICES TO AFFECTED FAMILIES WORLDWIDE. 8 8 11 20 0 3378398 3096737 0 5693 82382 24622 23495 3408713 3202614 1124784 1940710 0 373030 579149 0 197469 851901 758909 2349715 3278768 1058998 -76154 6111920 7077435 973275 1903126 5138645 5174309 TO FIND EFFECTIVE TREATMENTS AND A CURE FOR FANCONI ANEMIA AND TO PROVIDE EDUCATION AND SUPPORT SERVICES TO AFFECTED FAMILIES WORLDWIDE. false false 2532819 1940710 3000 SUPPORT OF RESEARCH INTO THE CAUSE AND CURE OF FANCONI ANEMIA 260652 PROVIDING EDUCATION AND SUPPORT TO FAMILIES AFFECTED BY FANCONI ANEMIA 2793471 true true false false false false false false false false false true false false false true true false false false true true false false false false false true false false false false false false false false false false true false false false false false false false false true 1 0 false 11 true false false false false false false false false false false X 8 8 true false false false false false false true true false false true true true true true true true true false AL AK AR CA CT FL GA IL KS KY ME MD MA MI MN NH NJ NM NY NC ND OH OK OR PA RI SC TN UT VA WA WV WI CO DC HI MS X X CYNTHIA PAPPAS 5416874658 1801 WILLAMETTE ST SUITE 200 EUGENE OR 97401 KEVIN MCQUEEN PRESIDENT 10.00 X X 0 0 0 MARK PEARL VICE PRESIDE 10.00 X X 0 0 0 SHARON SCHUMAN SECRETARY/TR 4.00 X X 0 0 0 BARRY RUBENSTEIN BOARD MEMBER 1.00 X 0 0 0 DAVID FIASCHETTI BOARD MEMBER 5.00 X 0 0 0 BRIAN HORRIGAN BOARD MEMBER 1.00 X 0 0 0 RICHARD GELINAS BOARD MEMBER 1.00 X 0 0 0 PETER PLESS BOARD MEMBER 1.00 X 0 0 0 CHRISTOPHER BYRD -THROUGH SEPT 2016 BOARD MEMBER 1.00 X 0 0 0 ANNETTE WAXBERG- THROUGH MAY 2016 BOARD MEMBER 1.00 X X 0 0 0 AMY FROHNMAYER- THROUGH OCT 2016 BOARD MEMBER 1.00 X 0 0 0 PAMELA NORR- THROUGH DEC 2016 EXECUTIVE DI 40.00 X 97073 0 12104 CYNTHIA PAPPAS- AS OF OCT 2016 EXECUTIVE DI 40.00 X 23581 0 526 LYNN FROHNMAYER BOARD ADVISO 10.00 X 0 0 0 120654 12630 false false false 3096737 89203 3096737 82382 82382 OTHER INCOME 900099 23495 23495 23495 3202614 23495 82382 1005105 1005105 935605 935605 135521 25829 91721 17971 358845 232017 63829 62999 5938 5938 35975 1022 34290 663 42870 24331 10734 7805 18208 18208 30186 5384 21331 3471 161505 104284 24306 32915 370320 338701 14335 17284 SPECIAL PROJECTS 69525 16775 374 52376 SCHOLARSHIPS 64049 64049 COMMUNICATIONS 43957 40163 1928 1866 MISCELLANEOUS 889 206 589 94 270 245 25 3278768 2793471 287828 197469 151 184 1394139 1880379 1126 4714697 5196872 1807 6111920 7077435 12824 25483 960451 1877643 973275 1903126 X 4138645 3684555 1000000 1489754 5138645 5174309 6111920 7077435 -76154 131550 -19732 X X false true X true false X 1579265 1870643 1719329 3378398 3096737 11644372 1579265 1870643 1719329 3378398 3096737 11644372 2317243 9327129 98735 79452 35113 5693 82382 301375 11945747 23495 0.78080 0.78310 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED INVESTMENTS - CDS & CASH SWEEP 2616510 F US EQUITIES 1549646 F TIPS BOND ETFS 653148 F INTERNATIONAL EQUITIES 377568 F REITS F 5196872 X 3314432 131550 131550 3182882 19732 19732 3202614 3259036 3259036 19732 19732 3278768 SCHEDULE D, PAGE 3, PART X FANCONI ANEMIA RESEARCH FUND, INC. IS EXEMPT FROM INCOME TAXES UNDER INTERNAL REVENUE CODE ("IRC") SECTION 501(C)(3) AND IS NOT A PRIVATE FOUNDATION WITHIN THE MEANING OF THE IRC AND AS AN ENTITY THAT QUALIFIES FOR DEDUCTIBLE CONTRIBUTIONS. ACCORDINGLY, NO PROVISION HAS BEEN MADE FOR INCOME TAXES IN THE FINANCIAL STATEMENTS. THE ORGANIZATION CONSIDERS ANY UNCERTAIN TAX POSITIONS CONSISTENT WITH GAAP. THE ORGANIZATION IS NO LONGER SUBJECT TO EXAMINATION BY FEDERAL OR OREGON TAXING AUTHORITIES FOR 2012 AND EARLIER YEARS. true MILANO, ITALY RESEARCH GRANT GENE THERAPY 175000 BARCELONA, SPAIN RESEARCH GRANT DRUG SCREENING 160000 BAVARIA, GERMANY RESEARCH GRANT REDUCING FANCONI AN. 183318 AMSTERDAM, NETHERLANDS RESEARCH GRANT CLINICAL MANAGEMENT 234320 VICTORIA, AUSTRALIA RESEARCH GRANT DETECTION/CHARACTERI 182967 935605 935605 GENE THERAPY 175000 DRUG SCREENING 160000 REDUCING FANCONI AN. 183318 CLINICAL MANAGEMENT 234320 DETECTION/CHARACTERI 182967 false false false false false false SCHEDULE F, PAGE 1, PART I, LINE 2 THE ORGANIZATION COMPILES A GRANT FILE FOR EACH GRANT RECIPIENT THAT HOUSES THE GRANT APPLICATION, REVIEWS CONDUCTED BY OUTSIDE REVIEWERS, THE PROPOSAL REVIEW COMMITTEE'S REPORT, A CV FOR ALL OF THOSE PARTICIPATING IN THE PROJECT AND A SIGNED ACCEPTANCE OF AWARD. THIS DOCUMENT MUST BE SIGNED BY THE PRINCIPAL INVESTIGATOR AND THE OFFICIAL SIGNING AUTHORITY OF THE INSTITUTION WHERE THE RESEARCH WILL BE PERFORMED. TO MONITOR THE USE OF FUNDS, FINANCIAL AND RESEARCH REPORTS ARE REQUIRED ON AN ANNUAL BASIS DURING THE LIFE OF THE GRANT AND REVIEWED BY THE DEPUTY DIRECTOR TO ENSURE FUNDS ARE BEING USED APPROPRIATELY IN ADDITION TO BEING REVIEWED BY THE PROPOSAL REVIEW COMMITTEE AND THE BOARD. SCHEDULE F, PAGE 1, PART I, LINE 3 MILANO, ITALY 175,000 0 BARCELONA, SPAIN 160,000 0 BAVARIA, GERMANY 183,318 0 AMSTERDAM, NETHERLANDS 234,320 0 VICTORIA, AUSTRALIA 182,967 0 SCHEDULE F, PAGE 5, PART V FURTHER INFORMATION ON TYPE OF SERVICE(S) BY REGION: MILANO, ITALY - INVESTIGATING THE IMPACT OF LENTIVIRAL TRANSDUCTION ON FANCONI ANEMIA HEMATOPOIETIC STEM CELLS FOR IMPROVED GENE THERAPY BARCELONA, SPAIN - DRUG SCREENING AND REPURPOSING IN FANCONI ANEMIA THERAPEUTICS (ACRONYM: REPAIR-FANC) BAVARIA, GERMANY - REDUCING THE BURDEN OF SQUAMOUS CELL CARCINOMA IN FANCONI ANEMIA AMSTERDAM, NETHERLANDS - IMPROVED CLINICAL MAMANGEMENT OF FA RELATED CANCER VIA A NOVEL FUNCTIONAL GENOMICS APPROACH VICTORIA, AUSTRALIA - DETECTION AND CHARACTERIZATION OF UBIQUITINATED FANCD2 AND FANCI true WHITEHEAD INST BIOMED RESEARCH 9 CAMBRIDGE CENTER CAMBRIDGE MA 021421479 061043412 160000 ENVIRONMENTS IMPACT CINCINNATI CHILDREN'S HOSPITAL 3333 BURNET AVE MLC 490 CINCINNATI OH 452293039 310833936 250000 PREVENTION/TREATMENT NATIONAL CANCER INSTITUTE 9000 ROCKVILLE PIKE BLDG RM 11-A-16 BETHESDA MD 20892 520858115 300000 HETEROZYGOTE CANCER CHILDREN'S HOSPITAL OF PHILADELPHIA 3615 CIVIC CENTER BOULEVARD PHILADELPHIA PA 191044318 231352166 204593 TARGETING LNK(SH2B3) NATIONAL CANCER INSTITUTE 9000 ROCKVILLE PIKE BLDG RM 11-A-16 BETHESDA MD 20892 520858115 75500 DEVELOPMENT TRAINING OREGON HEALTH & SCIENCE UNIVERSITY 3181 SW SAM JACKSON PARK RD PORTLAND OR 97239 931176109 10012 ANTIBODY RESEARCH SCHEDULE I, PAGE 1, PART I, LINE 2 THE ORGANIZATION COMPILES A GRANT FILE FOR EACH GRANT RECIPIENT THAT HOUSES THE GRANT APPLICATION, REVIEWS CONDUCTED BY OUTSIDE REVIEWERS, THE PROPOSAL REVIEW COMMITTEE'S REPORT, A CV FOR ALL OF THOSE PARTICIPATING IN THE PROJECT AND A SIGNED ACCEPTANCE OF AWARD. THIS DOCUMENT MUST BE SIGNED BY THE PRINCIPAL INVESTIGATOR AND THE OFFICIAL SIGNING AUTHORITY OF THE INSTITUTION WHERE THE RESEARCH WILL BE PERFORMED. TO MONITOR THE USE OF FUNDS, FINANCIAL AND RESEARCH REPORTS ARE REQUIRED ON AN ANNUAL BASIS DURING THE LIFE OF THE GRANT AND REVIEWED BY THE DEPUTY DIRECTOR TO ENSURE FUNDS ARE BEING USED APPROPRIATELY IN ADDITION TO BEING REVIEWED BY THE PROPOSAL REVIEW COMMITTEE AND THE BOARD. SCHEDULE I, PAGE 4, PART IV FURTHER DETAIL ON PURPOSE OF GRANT/ASSISTANCE BY LINE: PART II, LINE 1 - HOW ENVIRONMENT SHAPES THE CONSEQUENCES OF MUTATION WITHIN THE FANCONI ANEMIA PATHWAY PART II, LINE 2 - TARGETING LIPID METABOLISM IN FA FOR THE PREVENTION AND TREATMENT OF SQUAMOUS CELL CARCINOMA PART II, LINE 3 - CANCER IN HETEROZYGOTE CARRIERS OF FANCONI ANEMIA PART II, LINE 4 - TARGETING LNK (SH2B3) TO AMELIORATE HEMATOPOIETIC STEM/PROGENITOR DEFECTS IN FANCONI ANEMIA PART II, LINE 5 - A TRAINING GRANT FOR DEVELOPMENT OF A FANCONI ANEMIA COHORT IN MEXICO PART II, LINE 6 - TO ESTABLISH/CREATE ANTIBODIES TO USE FOR RESEARCH X 5 89203 FAIR MARKET VALUE false true false SCHEDULE M, PAGE 2, PART II ALL NON-CASH CONTRIBUTIONS ARE REVIEWED AND DEPOSITED ONCE A MONTH BY THE BOOKKEEPER, AND THEN ARE REVIEWED AGAIN DURING MONTH END CLOSING REPORT REVIEW BY THE DEPUTY AND EXECUTIVE DIRECTOR. FORM 990, PAGE 6, PART VI, LINE 2 AMY FROHNMAYER LYNN FROHNMAYER BRD MEMBER BRD ADVISOR FAMILY - MOTHER & DAUGHTER FORM 990, PAGE 6, PART VI, LINE 11B THE 990 WILL BE PREPARED IN TIME FOR THE FIRST BOARD MEETING OF THE YEAR AT WHICH TIME A FINAL DRAFT VERSION WILL BE SHARED WITH THE BOARD AND APPROVED BY VOTE PRIOR TO SUBMITTING THE 990 TO THE OFFICIALS. FORM 990, PAGE 6, PART VI, LINE 12C BOARD MEMBERS ANNUALLY STATE ANY REAL OR POTENTIAL CONFLICTS OF INTEREST ON A CONFLICT OF INTEREST DISCLOSURE FORM. FORM 990, PAGE 6, PART VI, LINE 15A NO INDEPENDENT REVIEW WAS CONDUCTED FOR THIS POSITION. WAGE FOR THIS POSITION IS SET BY THE BOARD PRESIDENT BY REVIEWING SELF- CONDUCTED MARKET RESEARCH. FORM 990, PAGE 6, PART VI, LINE 15B EMPLOYEE COMPENSATION WAS EVALUATED BY COLLECTING COMPARABLE DATA FOR NON- PROFIT, STATE, AND COUNTY SOURCES IN ADDITION TO WAGE ANALYSIS REVIEW BY INDEPENDENT PERSONS WHICH WAS THEN USED TO FORMULATE WAGES BY THE EXECUTIVE DIRECTOR AND APPROVED BY THE EXECUTIVE COMMITTEE BEFORE IMPLEMENTATION. FORM 990, PAGE 6, PART VI, LINE 17 MICHIGAN, MINNESOTA, NEW HAMPSHIRE, NEW JERSEY, NEW MEXICO, NEW YORK, NORTH CAROLINA, NORTH DAKOTA, OHIO, OKLAHOMA, OREGON, PENNSYLVANIA, RHODE ISLAND, SOUTH CAROLINA, TENNESSEE, UTAH, VIRGINIA, WASHINGTON, WEST VIRGINIA, WISCONSIN, COLORADO, DIST OF COLUMBIA, HAWAII, MISSISSIPPI FORM 990, PAGE 6, PART VI, LINE 19 WHEN GOVERNING DOCUMENTS OR THE CONFLICT OF INTEREST POLICY ARE REQUESTED, A COPY IS MADE AND MAILED TO THE REQUESTING PARTY. THE ANNUAL 990 AND AUDIT REPORT ARE ON THE ORGANIZATIONS WEBSITE AND COPIES ARE ALSO ISSUED WHEN REQUESTED. FORM 990, PAGE 12, PART XII, LINE 2C THE BUDGET & INVESTMENT COMMITTE PARTICIPATE IN THE SELECTION OF AN INDEPENDENT ACCOUNTANT. THE AUDIT OF THE FINANCIAL STATEMENTS IS OVERSEEN BY THE DEPUTY AND EXECUTIVE DIRECTORS AND THE FINANCIAL STATEMENTS ARE REVIEWED BY THE BOARD.